

IN THE DRAWINGS:

Please amend the drawings according to the attached set of figures, on which the amendments are indicated in red ink. Specifically, please replace in sequence 3 of Figure 3A amino acids 18H, 36E and 37L with 18R, 36D and 37V, respectively. Also, please replace in sequence 3 of Figure 3B, amino acids 447K and 506Q with 447E and 506E.

The attached replacement sheets, which include Figures 3A and 3B, replace the original sheets of drawings for Figures 3A and 3B.

Attachments following last page of this response:

Replacement Sheets (2 pages)

Annotated Sheets Showing Changes (2 pages)

Applicant : Manuel Vega, et. al
Serial No. : 10/022,390
Filed : December 17, 2001
Amendment and Response to Notice to Comply
Page : 4 of 7

Attorney's Docket No.: 17109-003001 / 912

IN THE SEQUENCE LISTING

Please replace the sequence listing in the above-captioned application with the attached substitute sequence listing. Two CD-R copies of the substitute sequence listing accompany this amendment and response.

REMARKS

Applicant hereby submits enclosures that fulfill the requirements under 37 C.F.R. §§1.821-1.825. Amendments to the specification insert the two CD-R copies of the substitute Sequence Listing and sequence identifiers in the specification. Minor typographical amendments are made to the specification and figures with regard to the sequence listing. No new matter has been added. Attached hereto is a marked-up version of the changes made to the specification by the current amendment. Any fees that may be due in connection with the filing of this paper or with this application may be charged to Deposit Account No. 06-1050. If a Petition for Extension of time is needed, this paper is to be considered such Petition.

The amendment of the paragraph beginning at page 5, line 25 - 31 identifies the nucleotide and amino acid SEQ ID Nos. for AAV-1, AAV-6, AAV-3, AAV-3B, AAV-4, AAV-2 and AAV-5 as being SEQ ID Nos. 736, 737; 738, 739; 740, 741; 742, 743; 744, 745; 746, 747; and 748, 749; respectively. This amendment finds basis, for example, in the substitute sequence listing which adds the respective nucleotide and amino acid sequences for the protein sequences shown in Figures 3A and 3B. The amendment of the paragraph beginning at page 9, line 3-19 replaces the GenBank Accession number for AAV-6 from "NC_001729" to -NC_001862.- NC_001729 is the GenBank Accession number for AAV-3 as identified in the specification on page 9, lines 9 - 10, whereas NC_001862 is the proper GenBank Accession number for AAV-6.

Amendments have been made to Figures 3A and 3B. Specifically, amino acids 18H, 36E, 37L, 447K and 506Q have been corrected to 18R, 36D, 37V, 447E and 506E, respectively. Basis for the amendment is found in the specification, for example, on page 6, line 2 in which sequence 3 of Figures 3A and 3B is identified as being AAV-3. Further basis can be found, for example, at page 9, lines 9 - 10 in which AAV-3 is identified by GenBank Accession No. NC_001729 and ATCC No. VR-681. Red ink markings of the changes to be incorporated are submitted with this amendment for approval by the Examiner. In addition, replacement sheets of drawings are submitted with this amendment.

Attached herewith are two CD-R copies of the substitute sequence listing, and a verified statement that the content of the computer readable copies are the same in accordance with 37 C.F.R §§1.821-1.825. The instant amendment seeks to amend the sequence listing by adding the

inadvertently omitted amino acid sequences listed in Figures 3A and 3B, along with their corresponding nucleotide sequences identified by their GenBank number on page 9, lines 8-14. These sequences have been designated as SEQ ID Nos. 736 – 749 in the substitute sequence listing. The amendment finds basis, for example, at page 6, lines 1 – 3 and page 9, lines 8 – 14 of the specification as well as in Figures 3A and 3B. In addition, items <140> and <141> of the sequence listing are amended to incorporate the now-available U.S. Application Serial number, 10/022,390, and the date on which the above-identified application was filed, December 17, 2001. The two computer-readable copies of the substitute sequence listing are titled 912SEQ.002.txt are identical to each other. The substitute sequence listing contains no new matter. These sequences are entered into the substitute sequence listing provided herewith.

No new matter is added.

* * *

Entry of this amendment and examination of the application are respectfully requested.

Respectfully submitted,

Stephanie Seidman
Reg. No. 33,779

Attorney Docket No. 17109-003001 / 912

Address all correspondence to:

Stephanie Seidman
Fish & Richardson P.C.
12390 El Camino Real
San Diego, California 92130
Telephone: (858) 678-5070
Facsimile: (202) 626-7796
email: seidman@fr.com

Applicant : Manuel Vega, et. al
Serial No. : 10/022,390
Filed : December 17, 2001
Amendment and Response to Notice to Comply
Page : 7 of 7

Attorney's Docket No.: 17109-003001 / 912

APPENDIX

ANNOTATED SHEET
FISH & RICHARDSON P.C.

Sheet 3 of 4

Title: MUTANT RECOMBINANT ADENO-ASSOCIATED VIRUSES
Applicants: Manuel Vega, *et al.* Attorney Docket No. 17109-003001 / 912
U.S. Serial No.: 10/022,390 Filing Date: December 17, 2001

FIGURE 3A

	10	20	30	40	50	60	
1	MPG	FYE	IV	IK	VP	SD	60
2	MPG	FYE	IV	IK	VP	SD	60
3	MPG	FYE	IV	IK	VP	SD	60
4	MPG	FYE	IV	IK	VP	SD	60
5	MPG	FYE	IV	IK	VP	SD	60
6	MPG	FYE	IV	IK	VP	SD	60
7	MAT	FYE	IV	VR	VP	SD	60
C	M**FYE**	:*VP*	D***H	LP	GIS	+SFV:WV*****WELPP*SD**+*L*EQ**LTVA****	
	70	80	90	100	110	120	
1	RD	FL	VQ	RR	RV	SK	120
2	RD	FL	VQ	RR	RV	SK	120
3	REF	L	VE	W	RR	RV	120
4	REF	L	VE	W	RR	RV	120
5	REF	L	VE	W	RR	RV	120
6	RD	FL	TE	W	RR	RV	120
7	RV	FL	Y	EW	N	K	119
C	R:FL++	+W***SK**E**F	VF	Q	FE	KG+	
	130	140	150	160	170	180	
1	YR	GI	EP	TL	PN	WF	180
2	YR	GI	EP	TL	PN	WF	180
3	YR	GI	EP	TL	PN	WF	180
4	YR	GI	EP	TL	PN	WF	180
5	YR	GI	EP	TL	PN	WF	180
6	YR	GI	EP	TL	PN	WF	180
7	FQ	GI	EP	Q	I	N	177
C	**G:EP:	***W*A*TK****	GG*N	KV	VD:	*YIP*YLLPK*QPELQWAWTN*::Y:*A*L	
	190	200	210	220	230	240	
1	NL	AE	R	K	L	V	240
2	NL	AE	R	K	L	V	240
3	NL	AE	R	K	L	V	240
4	NL	AE	R	K	L	V	240
5	NL	AE	R	K	L	V	240
6	NL	AE	R	K	L	V	240
7	NL	AE	R	K	L	V	236
C	NL+ER	KRLVA**L***SQ***Q****	***S**PVI*SKTS**YM*LV*WLV**	+GITSEK			
	250	260	270	280	290	300	
1	QW	IQ	ED	Q	A	S	300
2	QW	IQ	ED	Q	A	S	300
3	QW	IQ	ED	Q	A	S	300
4	QW	IQ	ED	Q	A	S	300
5	QW	IQ	ED	Q	A	S	300
6	QW	IQ	ED	Q	A	S	300
7	QW	IQ	EN	Q	E	S	296
C	QW	IQE	*Q*SY*SFN***NSRSQIKAALDNA:	KIM+LTK:A*DYLVG::**+DI::NRI*:			
	310	320	330	340	350	360	
1	I	L	E	L	N	G	360
2	I	L	E	L	N	G	360
3	I	L	E	L	N	G	360
4	I	L	E	L	N	G	360
5	I	L	E	M	N	G	360
6	I	L	E	M	N	G	360
7	I	F	E	M	N	G	356
C	I	*E	+NGY*P:YA:S***GW***:F*KRNT*WL*GPATTGKTNIAEAIAH+VPFYGCVNWT				

Title: MUTANT RECOMBINANT ADENO-ASSOCIATED VIRUSES
Applicants: Manuel Vega, *et al.* Attorney Docket No. 17109-003001 / 912
U.S. Serial No.: 10/022,390 Filing Date: December 17, 2001

	370	380	390	400	410	420	
1	NENFPFNDCVDKMWIWEEGKMTAKVVESAKAILGGSKVRVDQCKSSAQIDPTPVIIVTS						420
2	NENFPFNDCVDKMWIWEEGKMTAKVVESAKAILGGSKVRVDQCKSSAQIDPTPVIIVTS						420
3	NENFPFNDCVDKMWIWEEGKMTAKVVESAKAILGGSKVRVDQCKSSAQIEPTPVIIVTS						420
4	NENFPFNDCVDKMWIWEEGKMTAKVVESAKAILGGSKVRVDQCKSSAQIEPTPVIIVTS						420
5	NENFPFNDCVDKMWIWEEGKMTAKVVESAKAILGGSKVRVDQCKSSAQIDPTPVIIVTS						420
6	NENFPFNDCVDKMWIWEEGKMTAKVVESAKAILGGSKVRVDQCKSSAQIDPTPVIIVTS						420
7	NENFPFNDCVDKMLIWEEGKMTNKVVESAKAILGGSKVRVDQCKSSVQIDSTPVIIVTS						416
C	NENFPFNDCVDKM*IWEEGKMT*KVVESAKAILGGSKVRVDQCKSS*QI+*TPVIIVTS						
	430	440	450	460	470	480	
1	NTNMCVIDGNSTTFEHQOPLQDRMFKFELTRRLDHDGFKVTKQEVKEFFRWAQDHVTEV						480
2	NTNMCVIDGNSTTFEHQOPLQDRMFKFELTRRLDHDGFKVTKQEVKEFFRWAQDHVTEV						480
3	NTNMCVIDGNSTTFEHQOPLQDRMFKFELTRRLDHDGFKVTKQEVKDFFRWASDHVTDV						480
4	NTNMCVIDGNSTTFEHQOPLQDRMFKFELTRRLDHDGFKVTKQEVKDFFRWASDHVTDV						480
5	NTNMCVIDGNSTTFEHQOPLQDRMFKFELTKRRLDHDGFKVTKQEVKDFFRWASDHVTEV						480
6	NTNMCVIDGNSTTFEHQOPLQDRMFKFELTRRLDHDGFKVTKQEVKDFFRWAKDHVVEV						480
7	NTNMCVVVDGNSTTFEHQOPLQDRMFKFELTKRLPDHFGKITKQEVKDFFAWAKVNQVPV						476
C	NTNMC*V*DGNSTTFEHQOPL*DRMFKFELT+RL: *DFGK*TKQEVK+FF*WA:***+:V						
	490	500			510	520	
1	AHEFYVRKGGANKRPAPDDADKSEPKRA-----				CPSVADPSTSDAEG		522
2	AHEFYVRKGGANKRPAPDDADKSEPKRA-----				CPSVADPSTSDAEG		522
3	AHEFYVRKGGAKKR PASNDADVSEPKRQ-----				CTSLAQPTTSDAEA		522
4	AHEFYVRKGGAKKR PASNDADVSEPKRQ-----				CTSLAQPTTSDAEA		522
5	THEFYVRKGGARKRPAPNDADISEPKRA-----				CPSVAQPSTSDAEA		522
6	EHEFYVKGGAKKR PASPDADISEPKRV-----				RESVAQPSTSDAEA		522
7	THEFKVPRELAGTKGAEKSLKRPLGDVTNTSYKSLEKRARLSFVPETPRSSDVTVDPAPL						536
C	:HEF*V+***A:***A:****.*****:				+*:*:*:***A*:		
	530	540	550	560	570	580	
1	APVDFADRYQNKCSRHAGMLQMLFPCKTCERMNQNFNICFTHGTRDCSECFP--GVSESQ						580
2	APVDFADRYQNKCSRHAGMLQMLFPCKTCERMNQNFNICFTHGTRDCSECFP--GVSESQ						580
3	P-ADYADRYQNKCSRHVGMNLMFLFPCKTCERMNQISNVCFTHGQRDCGECFPGMSESQPV						581
4	P-ADYADRYQNKCSRHVGMNLMFLFPCKTCERMNQISNVCFTHGQRDCGECFPGMSESQPV						581
5	P-VDYADRYQNKCSRHVGMNLMFLPCRQCERMNQNVDCIFTHGVMDCAEFCF--VSESQPV						580
6	S-INYADRYQNKCSRHVGMNLMFLPCRQCERMNQNSNICFTHGQKDCLECFP--VSESQPV						579
7	RPLNWNWSRYDCKCDYHAQFDNISNKCDECEYLNRGKNGCICHNVTHCQICHG-----						588
C	:::+:**RY**KC**H:***:****C::CE**N*:*:C**H*:*:C.*C**..::+::::						
	590	600	610	620			
1	PVVRKRTRYKLCIAIHLLGRAPEIACSACDLVNVDLDDCVSEQ						623
2	PVVRKRTRYKLCIAIHLLGRAPEIACSACDLVNVDLDDCVSEQ						623
3	SVVKKKTYQKLCPIIHILGRAPEIACSACDLANVDLDDCVSEQ						624
4	SVVKKKTYQKLCPIIHILGRAPEIACSACDLANVDLDDCVSEQ						624
5	SVVRKRTRYQKLCPIIHIMGRAPEVACSACELANVDLDDCDMEQ						623
6	VSVVKKAYQKLCYIHHIMG-KVPDACTACDLVNVDLDDCIFEQ						621
7	-----IPPWEKENLSDFGDFDDANKEQ						610
C	:::+:**RY**KC**H:***:****C::CE**N*:*:C**H*:*:C.*C**..::+::::						